Dr. Sijia Lu
Dr. Sijia Lu is the Co-founder and CEO of Yikon Genomics, a leading solution-based single cell sequencing company based on the patented MALBAC® technology from Harvard University
Founded in 2012, Yikon Genomics is dedicated to the development and application of single-cell sequencing technologies in the fields of prenatal and postnatal care as well as early tumor diagnosis. Under the leadership of Dr. Lu, Yikon Genomics successfully invented and transformed a number of world-leading technologies in the fields of reproductive health, tumor screening and testing, and life sciences. The company has promoted the adoption of advanced technology in the provision of healthcare services in China, leveraging strategic partnerships to disseminate the diagnosis and treatment solutions through telemedicine and disruptive B2C models.
At present, Yikon Genomics has offices in Beijing, Shanghai, Jiangsu including presence in over 32 provinces and municipalities. It has established partnerships with over 400 large medical institutions across more than 20 countries including the United States, the United Kingdom, Russia, Japan, Thailand, Malaysia, and Cambodia
Sijia Lu holds a PhD from Harvard University, and an Executive MBA from Guanghua School of Management of Peking University and Kellogg School of Management of Northwestern University. He is an expert in high-throughput gene sequencing, co-inventor of MALBAC whole-genome amplification technology, inventor of NICS non-invasive embryo chromosome detection technology, and a representative at the Shanghai Municipal People's Congress in the People’s Republic of China. Dr. Lu holds more than 30 patents and published 35 papers in internationally renowned journals such as the "Science" and the "Cell"